A5105824279- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Mesenchymal stem cell research
- T-cell and B-cell Immunology
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Organ Transplantation Techniques and Outcomes
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Angiogenesis and VEGF in Cancer
- Prenatal Screening and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Transplantation: Methods and Outcomes
- Chronic Myeloid Leukemia Treatments
- Parvovirus B19 Infection Studies
- Virus-based gene therapy research
- Liver physiology and pathology
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Neonatal Respiratory Health Research
- Lymphoma Diagnosis and Treatment
- Lymphatic System and Diseases
- Childhood Cancer Survivors' Quality of Life
Karolinska Institutet
2009-2022
Karolinska University Hospital
2009-2018
Immune Therapy Holdings (Sweden)
2015
Institute for Transfusion Medicine
2009-2011
Xinjiang Medical University
2008
Umeå University
2006
Integrated Cardio Metabolic Centre
2000-2003
Sahlgrenska University Hospital
2002
Stockholm University College of Music Education
2001
Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD).We gave eight patients with steroid-refractory grades III-IV GVHD and one who had extensive chronic GVHD. dose median 1.0 (range 0.7 9)x10(6)/kg. No acute side-effects occurred after infusions. Six were treated once three twice. Two received from HLA-identical siblings, six haplo-identical family donors four unrelated mismatched donors.Acute...
Mesenchymal stromal cells (MSCs) are explored as a novel treatment for variety of medical conditions. Their fate after infusion is unclear, and long-term safety regarding malignant transformation ectopic tissue formation has not been addressed in patients. We examined autopsy material from 18 patients who had received human leukocyte antigen (HLA)-mismatched MSCs, 108 samples 15 were by PCR. No signs or tumors MSC-donor origin found on macroscopic histological examination. MSC donor DNA was...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over past 2 decades. Between 1992 and 2009, 953 patients were treated with HSCT, mainly for a hematologic malignancy. They divided according to 4 different time periods treatment: 1995, 1996 2000, 2001 2005, 2006 2009. Over years, many factors have changed considerably regarding patient age, diagnosis, disease stage, type donor, source, genomic HLA typing, dose, conditioning, treatment infections, use...
Background. Viral infections are major complications after allogeneic hematopoietic stem cell transplantation (HSCT). During posttransplant immunosuppression the regular T-cell control is compromised. Even if treatment strategies against caused by herpes viruses such as cytomegalovirus, Epstein-Barr virus, and adenovirus have improved, mortality rate still considerable. If primary antiviral therapy fails or cannot be tolerated, adoptive with virus-specific cytotoxic T cells (CTL) can utilized.
The endometrium is a dynamic, cyclically regenerating tissue: unique model of physiological angiogenesis in adults. However, the source new endothelial cells (ECs) for vessel regrowth obscure. We studied if male EC could be detected endometrial blood vessels female human or mouse recipients haematological stem from donors.Endometrial biopsies, obtained one patient after non-myeloablative allogeneic bone marrow transplantation and two controls, were analysed by immunohistochemistry CD34...
Abstract The placenta protects the fetus from mother's immune system. We have previously found that fetal membrane cells (FMCs) isolated term prevent alloreactivity in vitro. FMCs share many features with bone marrow-derived mesenchymal stromal (MSCs), which we introduced to treat severe acute graft-versus-host disease (GVHD). Here, tested for treatment of steroid-refractory GVHD. After two passages culture, approximately 109 were obtained one single placenta, although not all passage 0 and...
Background— Receptor tyrosine kinases that include vascular endothelial growth factor (VEGFR)-1, VEGFR-2, and Tie-2 regulate cardiovascular development physiological pathological angiogenesis. We were interested in the phenotypic functional characterization of peripheral blood cells expressing these receptors their therapeutic potential injury. Methods Results— VEGFR-1 + , VEGFR-2 constituted ≈3.0±0.2%, 0.8±0.5%, 2.0±0.3%, respectively, total population mononuclear blood. Phenotypic analysis...
It has been debated whether mixed chimerism (MC) is correlated to a decreased incidence of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT).Between September 1996 and April 1999 we analyzed 102 patients for MC in the T-cell fraction post SCT, using PCR amplification variable numbers tandem repeat (VNTR) loci. All samples, taken regularly were separated anti-CD3 immunomagnetic beads.T-cell was detected 58 out (57%). Patient characteristics comparable MC- donor...
Nonmyeloablative (NM) conditioning and reduced-intensity (RIC) are increasingly used for allogeneic hematopoietic stem-cell transplantation. Such regimens have not been compared.The primary endpoint was graft-versus-host disease (GVHD). Secondary endpoints included transfusions, engraftment, transplant-related mortality (TRM). NM (n=24) consisted of fludarabine 2-Gy total-body irradiation followed by immunosuppression with cyclosporine A (CsA) combined mycophenolate mofetil (MMF). The RIC...